Mankind Pharma Q1: consolidated PAT up 29% YoY to ₹574 Cr on EBITDA margin expansion
PAT +29.12% YoY · revenue +12.89% · margins expanding
₹4,030.59 Cr
+12.89% YoY
₹574.09 Cr
+29.12% YoY
14.09%
+1.9pp YoY
₹13.76
Mankind Pharma opened FY27 with a clean double-digit print: consolidated revenue rose 12.9% YoY to ₹4,030.6 Cr and net profit climbed 29.1% to ₹574.1 Cr (₹568.1 Cr attributable to the parent), with no exceptional items on either side of the comparison — so the reported growth is also the underlying growth. Reported EPS was ₹13.76. Sequentially the topline gained 17.1% and PAT edged up only 2.6% over Q4FY26's ₹559.4 Cr, a gap that is a tax and base effect rather than a slowdown.
Q1 FY-2027 vs prior quarters
The quality of the quarter sits in the margin bridge. Consolidated EBITDA margin expanded to roughly 26.3% from about 23.7% a year ago (net profit margin 14.2% vs 12.2%), helped by a lower gross-input and other-expenses drag versus the BSV-loaded year-ago base. Notably, profit before tax jumped ~42% YoY to ₹769.5 Cr, but a normalised effective tax rate of 25.4% (against an unusually low 17.7% in Q1FY26) held PAT growth to 29% — the tax line, not operations, is why the bottom line trails PBT. Standalone told a slightly stronger story (PAT +34.5% to ₹558.5 Cr on revenue +15.3%), with the ~5pt gap to consolidated reflecting drag from overseas and newly consolidated BSV subsidiaries; readers seeing the standalone number elsewhere should treat both as correct.
The stock went into the print at ₹2,580.8, up 3.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management projects double-digit revenue growth for FY27, aiming to outperform the IPM. They also anticipate improved EBITDA margins, guiding for a range of 25.5% to 26.5%. The strategic direction emphasizes a continued shift towards specialty and chronic therapies, driven by R&D-led innovation and a focus on building
— This quarter: met
Against management's own FY27 guidance from the Q4 concall — double-digit revenue growth and a 25.5–26.5% EBITDA margin band — this print lands squarely on plan: +12.9% revenue and a ~26.3% margin at the top of the guided range, consistent with the confident, bullish tone struck in May. No formal pre-result Street consensus was found in published previews, so the beat/miss call versus the sell-side is left open; on the company's own bar, it is an on-track quarter.
W1
Effective tax rate: whether it normalises around 25% for the rest of FY27 vs the low 17.7% base that flattered year-ago PAT
W2
EBITDA margin holding the top of the guided 25.5–26.5% band as BSV women's-health integration and Vadodara biotech capex ramp
W3
Standalone-vs-consolidated PAT gap (~5pts) — trajectory of overseas and BSV subsidiary profitability narrowing the drag
Clean digital PDF, unmodified limited-review conclusion. No exceptional items this quarter (current & year-ago both clean; Q4FY26 one-offs excluded from YoY). Consolidated PAT 574.09 is total for period; attributable to parent 568.06, NCI 6.03; EPS is parent-based. Year-ago Q1FY26 restated for BSV common-control business combination. Effective tax rate rose to 25.4% (vs 17.7% YoY), capping PAT growth below PBT's +42%.
Guidance met, but acute recovery unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met prior guidance on revenue growth, EBITDA margins, and margin expansion. Achieved as promised. No numeric cuts, but scope narrowed.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Mankind delivered Q1 in line with prior guidance (12.9% revenue growth, EBITDA margin 26.3% within 25.5–26.5% band). Chronic shift underway (40% share, +80 bps), acute recovery evident (10.9% vs –6% prior), volume momentum improving (4.7% vs 2.3%). However, management walked back IPM outperformance ambition (now claiming double-digit, not 1.3–1.7x), GLP-1 launch delayed due to competitive pressure, and working capital elevated due to inventory. Tax headwind now permanent (25.4% vs 17.7% prior). Execution on structural recovery is credible but pace uncertain.
₹4031 Cr
Revenue · +12.9% YoY₹574 Cr
Reported PAT · +29.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue ₹4,031 Cr, up 13% YoY with EBITDA 26.3%
METDelivered ₹4,030.6 Cr (+12.9%), OPM 26.2%. Rounding match.
PAT grew 29.1% YoY to ₹574 Cr, margin improved 170 bps to 14.2%
METDelivered ₹574.1 Cr (+29.1%), NPM 14.1%. Match.
EBITDA margin improved 250 bps YoY to 26.3%
METOPM 26.2%, consistent with 26.3% EBITDA claim.
Chronic share (excl. BSV) increased 80 bps to 40%
METChronic portfolio grew 15.8% YoY with volume at 4.7% (up 220 bps). Share gain evidenced.
EBITDA guidance maintained at 25.5–26.5%
METAchieved 26.3%, within range at top. No cut or raise.
Guidance: double-digit revenue growth for FY27
METQ1 at 12.9% (low double-digit). Domestic +11% excl. CHC. Volume recovery 4.7% suggests momentum building.
Working capital at 52 days; expect normalization by year-end
PartialUp from 48 days (Q1 FY26) due to elevated inventory buffering price increases. Management expects rationalization; no concrete timeline given.
Consumer Healthcare growth softer; but market share gains in Manforce, Preganews, Gas-o-fast
PartialCHC 3.8% growth (weak). Modern trade/e-com +38%. Market share claim unverified from transcript; management references 'increased' but no data.
Earnings quality
What changed since the last call
IPM outperformance aspirations reset
DowngradePrior: aiming for 1.3–1.7x IPM growth. Current: 'we never said we'd beat IPM' (Rajeev). Now guiding for double-digit (matching IPM). This is a tactical step-back.
GLP-1 launch strategy clarified as delayed
DowngradeWas expected to launch in first wave. Delayed due to attrition cleanup + competitive pricing risk. Now running as therapy bundle (gynaec + diabetes + supplements), not standalone molecule. Near-term NIL contribution.
EBITDA guidance maintained at 25.5–26.5%
NeutralNo change. Achieved 26.3% in Q1. Reaffirmed despite West Asia cost headwinds, suggesting confidence in gross margin defense.
Capex trajectory on track for 6–7% of revenue
NeutralQ1 at 4.9% (below guidance). Biotech facility added/enhanced; no new facility announcements. Capex timing flexibility signaled.
Consumer Healthcare outlook upgraded (slightly)
UpgradeQ1 softness (3.8%) acknowledged; guidance for Q2+ is 'high single-digit to double-digit'. Market share gains in Manforce/Preganews/Gas-o-fast noted. Modern trade +38% YoY compensating for cash & carry exit.
The Q&A
Analysts pressed on GLP-1 delay (Kunal, Ritika repeated this 3–4 times), acute recovery sustainability (Sidharth), covered market erosion (Kunal), and gross margin conservatism (Neha). Management held firm on strategy (GLP delayed = price-war avoidance, not failure), but did not fully satisfy on near-term acceleration. Tone was defensive but reasoned.
India growth, IPM outperformance — Pankaj Tibrewal, Ikigai Asset Manager
AnsweredAlready returned to double-digit growth. Quality improved: Chronic +15.8%, Acute 10.9%, BSV strong. Four structural levers: Chronic mix 40%→50%, hospital penetration expansion, new division Vistar, underpenetrated states. Will progressively outperform.
BSV guidance — Pankaj Tibrewal, Ikigai
AnsweredLast year early teens, this quarter 21%. Guidance high double-digit (high teens). Domestic 17%, international 25%. Well-spread across segments.
Working capital, inventory — Rashmi Shetty, Dolat Capital
PartialExpect to come down by year-end due to price advantages. Inventory slightly above normal; rationalization expected in coming quarters.
Gross margin guidance conservatism — Rashmi Shetty, Dolat
AnsweredOnly caveat: West Asia crisis commodity/dollar headwinds. Taking conservative approach. Overall EBITDA guidance unchanged 25.5–26.5%.
Cash EPS calculation method — Kunal Dhamesha, Macquarie
DodgedCash EPS is after depreciation, amortization, and impairment—cash portion. Roughly 50% allocation to acquisition-related. Will clarify offline.
Covered market erosion vs IPM — Kunal Dhamesha, Macquarie
AnsweredCovered market improved: FY21 56%→FY26 74%. Launched insulin, DPP-4, SGLT2, respiratory inhalers, CNS in-licensed. No meaningful change in relative coverage. Rank improved from 10→7 in diabetes.
GLP-1 launch delay rationale — Kunal Dhamesha, Macquarie
PartialNot cautious, strategic. Let 35–40 brands compete, massive price war. Taking therapy approach instead (gynaec + diabetes + supplements). Avoiding resource waste on hypercompetitive molecule. Launched in two segments already.
New product launches softer — Neha Manpuria, Bank of America
AnsweredLaunches very strategic. Make each big (Vonoprazan #1, Empagliflozin top 3). Selective, not volume. This is strategic move, not a lag to close.
Rivotril acquisition potential — Bino Pathiparampil, Elara
AnsweredAspiration is there, will take time. CNS is specialist, textbook brand. Building gold CNS portfolio. Key is entry to specialist doctors first.
Reorganization green shoots, attrition metrics — Sidharth Negandhi
AnsweredAcute: -2.5% (Q2)→13.6% (Q1). Gastro, Vitamins, Gynaec sequential improvement. Attrition dropped significantly, back to normal. Recovery on strong foundation.
Cash & carry discontinuation impact — Sidharth Negandhi
AnsweredMarket dynamic: general trade losing to e-commerce/modern trade. Same consumer, different channels. Modern trade/e-com share 11%→15%, +38% growth compensating. Overall market softer.
Semaglutide launch delay — Ritika Agarwal, ValueQuest
PartialNever claimed first few companies to launch. Couldn't launch in first phase due to company corrections (attrition). Strategic call to avoid price war. Launched in two segments with therapy approach (KOL-led).
Export business growth drivers — Rashmi Shetty, Dolat
AnsweredBSV +25%, Mankind+BSV guidance high teens. US launches, currency tailwind 12–13%. Ophthal product (prior one-off) now in base since FY25.
BSV domestic/export mix — Rashmi Shetty, Dolat
AnsweredFY26: 50–50. This year expected similar range ±2%.
Consumer Healthcare Q2 onwards guidance — Gourav Bhama, JM Financial
AnsweredHigh single-digit to double-digit.
BSV integration approach — Shirsh Sawarna, Bernstein
AnsweredBSV run independently both domestic/international. Tweaked management, added biotech facility. Gynaec coverage 33k→37k, IVF 80% reach, +35% growth. International: new approvals (Russia), upcoming FSH approvals.
Acute segment recovery drivers — Shirsh Sawarna, Bernstein
Answered60% of business from Acute. Relationship and face value matter. Removed people 18 months back, recovery on strong foundation. Prescription-driven policy. Never claimed to beat IPM. Double-digit growth target, EBITDA 25.5–26.6%.
Guidance
FY27 double-digit growth (maintained)
HighQ1 delivered 12.9%. Domestic (excl. CHC) 11%, BSV strong, international 29%. Structural levers (Chronic mix, acute recovery, Vistar launch, hospital expansion, underpenetrated states) support sustain.
EBITDA 25.5–26.5% for FY27 (maintained)
HighQ1 achieved 26.3% (mid-range, near top). Gross margin guidance 71%+ (conservative vs 72.8% Q1 achieved) due to West Asia cost headwinds. Operating leverage from fixed cost absorption.
Gross margin >71% (vs 72.8% Q1)
HighConservative guidance accounts for commodity/dollar inflation. Price increases already taken; expect some margin compression from cost inflation, but offset by Chronic mix and efficiency.
Capex 6–7% of revenue for FY27
MediumQ1 at 4.9% (below guidance). Biotech facility added/enhanced. Timing flexibility signaled; second half expected to have higher spend.
Risks the call surfaced
Acute business execution
MediumAcute 60% of portfolio; recovered to 10.9% but still below historical 1.3–1.7x IPM. Relationship-based (face-to-face matters). 18-month cleanup may not be sufficient.
GLP-1 competitive risk
Medium35–40 brands launched; management chose to delay and avoid price war. Therapy bundling (gynaec+diabetes+supplements) untested. If early movers capture share and pricing stabilizes, Mankind's late entry may face difficult economics.
Working capital deterioration
MediumWC days increased from 48 to 52 due to elevated inventory buffering price increases. If dollar/commodity costs remain high through FY27, normalization may be delayed, impacting cash flow.
Gross margin pressure
MediumQ1 achieved 72.8%, but management guided conservatively to 71%+ citing West Asia geopolitical risk. If oil/shipping costs spike or conflict escalates, gross margin could compress to 70% or below.
Consumer Healthcare channel shift
LowQ1 Consumer Healthcare growth soft (3.8%). Cash & carry discontinuation to protect general trade didn't yield expected higher GT sales. Modern trade/e-com up 38% but from lower base. Channel mix transition uncertain.
Management
Score 7/10. Clear on strategy and numbers. Transparent on headwinds (tax, inflation, West Asia, WC). Measured tone, not reflexively optimistic. Some Q&A deflection on GLP-1 delay and covered market shift. Met prior guidance on revenue growth (12.9%) and EBITDA (26.3%). Chronic shift demonstrable (40% share, +80 bps), acute recovery evident (10.9%). No misses on numeric commitments. Capex track record solid.
1 · Q2–Q4 FY27
Acute recovery sustain; target 10% growth sustainable
2 · FY27 full year
Chronic share reaches 42–43% on sustained momentum
3 · Q2 onwards
Consumer Healthcare recovery to high single-digit/double-digit post cash & carry exit
Execution on structural recovery is credible but pace uncertain.
Expect momentum on scale; watch how divestment reshapes the play
Mankind Pharma reports Q1 FY27 on July 30 with FY26's 17% revenue growth as the baseline. The Street will focus on domestic pharma momentum, margin resilience, and capital deployment strategy post-Broadway exit.
What to expect
Mankind Pharma's Q1 FY27 print will be judged against two pillars: sustained domestic pharma momentum, and credible capital redeployment post-divestment. FY26 delivered 17% revenue growth (₹14,278 Cr) and Q4 grew 11.8% on-plan. The Street will be watching for: (1) whether Q1 sustains Q4's growth trajectory into the new fiscal, (2) margin profile and whether operational leverage holds, and (3) management's articulation of how the ₹49 Cr Broadway exit and Netherlands subsidiary fit the medium-term playbook.
~₹3,400–3,500 Cr
tracking Q4's 11–13% growth run-rate; on-plan implies mid-teens YoY
tracking prior trajectory
Street expects operational leverage to hold; watch for pricing vs volume mix
subsidiary contribution
Upakarma (acquired Jan 2025, now 100% held) drives non-pharma portfolio
Netherlands SPV + Broadway exit
signifies shift toward export licensing and non-core pruning; shape FY27 growth vector
A strong quarter = revenue growth sustaining 12%+ YoY, EBITDA margin flat-to-up QoQ (protecting ~22–24% handle), and management commentary tying the divestment proceeds to strategic M&A or R&D capex. A weak quarter = growth slipping below 8% YoY, margin compression >100bp, or vague capital deployment guidance post-Broadway, signaling execution risk or margin pressure from competition.
Is the company on track?
Mankind has delivered against FY26 guidance: 17% topline growth and margin resilience. No formal FY27 full-year guidance has been disclosed in filings scanned, so Q1 will be judged tactically on growth continuity and operationally on margin protection. FII ownership edged down 110bp (11.34% Q3 → 10.24% Q4), a modest headwind; domestic and promoter holding steady suggests conviction at these levels. The stock trades ₹2507.2, -4.99% from its 52-week high of ₹2639, but +31% from the ₹1910 low — a neutral technicals setup (RSI 46.1) into the result.
What the Street says
Since last quarter — the filings scan
1 · Broadway Hospitality divestment (₹49 Cr, July 11)
Board approved exit of 100% stake in wholly-owned subsidiary. Non-pharma play; proceeds signal capital return or redeployment into core/adjacent. Watch for management's articulation on use-of-proceeds in the result call.
2 · Netherlands subsidiary incorporation (July 11)
New SPV setup signals export/licensing strategy or intellectual property structuring for European expansion. Not material to Q1 results but strategically relevant; clarify intent on the call.
3 · FY26 Annual Report & 35th AGM (August 4)
Standard governance; no surprising disclosures flagged. AGM post-result will approve FY26 audit and may signal management's FY27 outlook.
4 · Insider trading window closure (June 25)
Trading window closed from July 1 to 48h post-result announcement — routine pre-result compliance; no signal content.
5 · FII step-down (110bp Q3→Q4)
FII ownership declined from 11.34% to 10.24%; DII and promoter holding steady (72.66% promoter). Modest foreign interest loss; domestic backing intact.
Mankind Pharma's Q1 FY27 result arrives on July 30 with a clear setup: the market wants to see whether FY26's 17% growth momentum can carry into FY27, whether margins hold, and what the Board's capital allocation (Broadway exit, Netherlands SPV) means for the medium term. The stock, trading -5% from its 52-week high, is positioned for a beat or miss to shift the narrative on growth legs and valuation.
The three things to watch: (1) Revenue growth rate (target: 12%+ YoY, mid-teens for on-plan); (2) EBITDA margin trajectory (protect 22–24% range; compression >100bp flags pressure); (3) Management's FY27 outlook and capital deployment roadmap (SPV intent, use of Broadway proceeds). No forecast here — just the frame. The Street will decide if the quarter delivered.